About

I'm a board-certified psychiatrist based in Portland, seeing adults across Oregon by telehealth and consulting for legal teams, clinicians, and public agencies.

I trained in adult psychiatry at Oregon Health & Science University, where I later served as an assistant professor, supervised physicians in training, and founded the OHSU Psilocybin Education & Assessment Collaborative for Excellence (PEACE), a consultation service for patients with complex medical and psychiatric needs seeking state-regulated psilocybin services. I remain OHSU affiliate/volunteer faculty.

Writing has run alongside medicine for me. In medical school I co-founded a medical humanities journal that has continued to publish annually for over 10 years, and I still write poetry and fiction. That attention to story shapes how I listen, along with a long practice of zen meditation.

Education & Trainings

• Adult psychiatry residency, Oregon Health & Science University
• Doctor of Medicine, University of Central Florida
• Bachelor of Science in Psychology, University of Oregon
• Board certified in psychiatry, American Board of Psychiatry and Neurology
• Advanced certification in Psychedelic Harm Reduction & Integration (PHRI), Fluence
• MDMA Therapy Training Program, Part A, Multidisciplinary Association for Psychedelic Studies (MAPS)
• Narrative medicine facilitator training, Northwest Narrative Medicine Collaborative
• Fundamentals of psychoanalysis, Oregon Psychoanalytic Center
• Physician training in asylum evaluations, Philadelphia Human Rights Clinic, University of Pennsylvania
• Psychedelic equity training, Portland Psychedelic Society
• Physician peer support specialist and peer-to-peer suicide prevention training, OHSU
• Good Clinical Practice certification for clinical research (CITI Program and NIH)
• Austen Riggs Award for Excellence in Psychotherapy

Research

• Lead author, systematic review of interactions between psychiatric medications and MDMA or psilocybin, Psychopharmacology (2022)
• Study physician, Portland Psychotherapy, for FDA-regulated clinical trials of psychedelic-assisted treatments: MDMA-assisted therapy for social anxiety disorder (NCT05138068 (opens in a new tab)) and Beckley Psytech's 5-MeO-DMT trial for treatment-resistant depression (NCT05870540 (opens in a new tab)). I assessed and enrolled participants, reviewed their medical records, and medically supervised and authorized each dose of the study drug.
• Co-author, studies on risk-reduction consultation (Frontiers in Public Health, 2026) and drug-use stigma (Journal of Psychedelic Studies, 2024)
• Data safety monitoring board member for clinical trials of MDMA- and psilocybin-assisted treatments:
  • Chair, MDMA-assisted therapy for pathological narcissism, University of Washington (NCT06565494 (opens in a new tab))
  • Board member, psilocybin for co-occurring PTSD and alcohol use disorder in veterans and first responders, University of Washington (NCT06853912 (opens in a new tab))
  • Board member, psilocybin-enhanced psychotherapy for methamphetamine use disorder in veterans, VA Portland (NCT04982796 (opens in a new tab))

Advising

• Vice-chair and subcommittee co-chair, Oregon Psilocybin Advisory Board, Oregon Health Authority (appointed by Governor Kotek)
• Expert consultant, Oregon Public Defense Commission
• Founder, OHSU Psilocybin Education & Assessment Collaborative for Excellence (PEACE) consultation service
• Advisor to public health and nonprofit organizations, including Chile's Ministry of Health and the MIND Foundation in Berlin